ArticleUrology research & practice2025
Biochemical and Histological Characterization of Sorcin Overexpression in Patients Who Underwent Radical Prostatectomy.
Article in Urology research & practice, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Sorcin, a signaling molecule, has recently emerged as a significant focus within cancer research. This study aimed to compare histopathology results with serum sorcin level and tissue sorcin immunohistochemical expression in patients who underwent radical prostatectomy (RP). Methods: A total of 81 patients who underwent RP between December 2017 and June 2019 due to prostate cancer (PCa) and had not received any previous treatment were included in the study. Patients attended regular follow-up appointments for at least 24 months. In order to compare serum sorcin levels, the control group consisted of 67 healthy men. Demographic data of participants were recorded. In the PCa group, pathology data from both Transrectal ultrasound-guided biopsy and RP were documented. Results: Prostate-specific antigen (PSA) and sorcin levels of PCa patients were found to be higher than the control group (P < .001, P = .02). In the comparison of sorcin levels and sorcin staining percentages of PCa patients with histopathological and clinical findings; while sorcin levels were found to be higher in patients with positive lymph nodes (P = .018) and with biochemical recurrence (P = .049), no significant difference was found in any histopathological finding in terms of sorcin staining percentages. In an receiver operating characteristic curve analysis calculation for sorcin levels in PCa patients, AUC = 0.563 and when the cut-off value was taken as 0.415 ng/mL, 59.3% sensitivity 60.1% specificity was determined. Conclusion: Sorcin was found to be higher in PCa compared to healthy males. In addition, high International Society of Urological Pathology grade groups were observed in patients with high sorcin levels.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.